Takeda Pharmaceutical (TAK) Other Non-Current Assets (2017 - 2026)

Takeda Pharmaceutical has reported Other Non-Current Assets for 10 years, with the latest figure at $503.8 million in Q2 2026.

• On a quarterly basis, Other Non-Current Assets rose 6.33% year-over-year to $503.8 million in Q2 2026; TTM through Jun 2026 was $503.8 million, a 6.33% increase from a year earlier, with the FY2026 full-year figure at $491.1 million, up 6.43% from the prior year.
• Other Non-Current Assets was $503.8 million for Q2 2026 at Takeda Pharmaceutical, up from $491.1 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $710.9 million in Q1 2022, with the low at $345.6 million in Q1 2024.
• Average Other Non-Current Assets over 5 years is $506.8 million, with a median of $483.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets slumped 32.97% in 2023, then surged 55.3% in 2024.
• Over 5 years, Other Non-Current Assets stood at $472.6 million in 2022, then fell by 21.7% to $370.1 million in 2023, then surged by 31.81% to $487.8 million in 2024, then rose by 3.63% to $505.5 million in 2025, then slipped by 0.34% to $503.8 million in 2026.
• The last three Other Non-Current Assets figures came in at $503.8 million (Q2 2026), $491.1 million (Q1 2026), and $505.5 million (Q4 2025), per Business Quant data.